ClinicalTrials.gg
Active, not recruitingNCT05497804Updated Nov 2, 2026Results posted

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

A Phase 2 interventional study of Bone Marrow Aspiration and Biopsy and Carfilzomib in ISS Stage III Plasma Cell Myeloma and Multiple Myeloma, sponsored by Mayo Clinic. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
96th of 113
17 · median 54
Started
2022
with 4 others
Phase 2
50 of 113
6 open now
Primary completion
2026-02
later than 10 of 38 live
Registered
100th of 113
by date
Lead sponsor
4 of 113
Mayo Clinic

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 96th largest by enrollment, is one of 5 that started in 2022, is one of 50 in phase 2, reaches primary completion later than 10 of the 38 other live ones, and was the 100th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the rate of sustained minimal residual disease (MRD) negativity (MRD negative status at any point, with a repeated MRD negative status one year later) in subjects with high-risk multiple myeloma.

SECONDARY OBJECTIVES:

I. To describe the toxicities associated with this treatment approach in subjects with high-risk multiple myeloma (MM).

II. To estimate the overall response rate, very good partial response (VGPR) or better rate and complete response (CR) rate at the end of induction, end of consolidation, end of maintenance and at two years after the completion of treatment.

III. To estimate the progression-free survival and overall survival rate.

CORRELATIVE RESEARCH OBJECTIVES:

I. To describe the clonal architecture through a combination of genomic, epigenomic, proteomic and metabolomic studies before and after treatment, in subjects with high-risk MM.

II. To describe the bone marrow microenvironment through various stages of treatment and the time of MRD negative state and at time of relapse.

OUTLINE:

INDUCTION: Patients receive carfilzomib intravenously (IV) on days 1, 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide orally (PO) days 1-21 of each cycle, daratumumab subcutaneously (SC) days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.

Additionally, patients undergo bone marrow aspirate and biopsy, blood sample collection, echocardiography (ECHO) or multigated acquisition (MUGA) scan, and magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET)/CT throughout the study. Patients also undergo chest radiography (x-ray) during screening.

After completion of study treatment, patients are followed up every 6 months for up to 10 years.

03

Conditions studied

  • ISS Stage III Plasma Cell Myeloma
  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PRE-REGISTRATION-INCLUSION CRITERIA:
  • Age >= 18 years and =\< 80 years.
  • Patient must have suspected or confirmed newly diagnosed multiple myeloma by International Myeloma Working Group (IMWG) criteria.
  • (ECOG) performance status (PS) 0 or 1.
  • Provide informed written consent.
  • Willing to return to enrolling institution for follow-up during the active treatment phase of the trial.
  • Willing to provide blood and bone marrow samples for planned research.
  • > 6 months.
  • Able to take aspirin (325 mg) daily as prophylactic anticoagulation.

    • Note: subjects intolerant to aspirin may use warfarin, novel oral anticoagulants, or low dose molecular weight heparin.
  • Patients must have monoclonal protein studies (serum free light chain assay, serum immunofixation or serum matrix-assisted laser desorption ionization time-of-flight mass-spectrometry [MASS-FIX]) at time of diagnosis before induction therapy initiated and available for review to be enrolled. Note: Patients are allowed to participate in this study if urine electrophoresis immunofixation study was not done at time of diagnosis or cannot be obtained
  • REGISTRATION-INCLUSION CRITERIA:
  • High risk myeloma, which is untreated, defined as any two of:

    • Beta-2 microglobulin >5.5
    • Gain or amplification of chr1q
    • del17p or monosomy 17 or TP53 mutation (if known)
    • t(4;14) or t(14;16)
    • >= 5% circulating plasma cells
    • presence of extramedullary disease (does not include bone contiguous disease)
  • >= 30 mL/min (using Cockroft-Gault equation) (obtained =\< 14 days prior to registration).
  • (ANC) >= 1000/mm\^3 (without the use of growth factors) (obtained =\< 14 days prior to registration).
  • count >= 75000/mm\^3 (obtained =\< 14 days prior to registration).
  • >= 8.0 g/dL.
  • Total =\< 1.5 x (ULN) (obtained =\< 14 days prior to registration).
  • (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (obtained =\< 14 days prior to registration).
  • Registration must be completed =\< 30 days after pre-registration.
  • Patients must not have received more than one cycle of treatment between pre-registration and registration.
  • All 4 drugs in the study regimen approved by insurance.
  • (LVEF) >= 40% =\< 30 days prior to pre-registration

Exclusion criteria

Exclusion Criteria:

  • PRE-REGISTRATION EXCLUSION:
  • Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, light chain amyloidosis with organ involvement.
  • Diagnosed or treated for another =\< 1 year prior to pre- registration or previously diagnosed with another malignancy and have any evidence of residual disease.

    • NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  • Other co-morbidity which would interfere with subject's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease.
  • Other concurrent chemotherapy, or any ancillary therapy considered . NOTE: Concurrent chemotherapy is any treatment not related to multiple myeloma.

    • NOTE: Concurrent chemotherapy is any treatment not related to multiple myeloma
    • NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment.
  • Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain =\< 30 days prior to registration.
  • Major surgery =\< 14 days prior to pre-registration.
  • Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Known allergies, , or intolerance to , monoclonal antibodies or human proteins, or their (refer to respective package inserts or investigator's brochure) or known sensitivity to mammalian-derived products. Known allergies, hypersensitivity, or intolerance to trial drugs.
  • Inability to comply with protocol/procedures.
  • Received prior treatment for multiple myeloma prior to pre-registration. Note: results can still be pending as long as the tests have been performed
  • REGISTRATION-EXCLUSION CRITERIA:
  • If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

    • Pregnant women
    • Nursing women
    • Men or women of who are unwilling to employ adequate (per protocol).
  • Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.

    • Note: Prior to trial entry, any (ECG) abnormality at screening must be documented by the investigator as not medically relevant.
  • (NYHA) II, III, IV heart failure.
  • Known (HIV) positive.
  • Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.

    • EXCEPTION: subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
  • Known or suspected active infection.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment (combination chemotherapy)

    INDUCTION: Patients receive carfilzomib IV on days 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide PO days 1-21 of each cycle, daratumumab SC days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy, MRI and, CT/PET.

    Procedure: Bone Marrow Aspiration and Biopsy · Drug: Carfilzomib · Procedure: Computed Tomography · Biological: Daratumumab · Drug: Dexamethasone · Drug: Lenalidomide · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Procedure: Multigated Acquisition Scan · Procedure: Biospecimen Collection · Procedure: Echocardiography · Procedure: Chest Radiography

Interventions

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow aspiration and biopsy

  • Given IV

    Also known as: Kyprolis, PR-171

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography

  • BiologicalDaratumumab

    Given SC

    Also known as: Darzalex, HuMax-CD38, JNJ-54767414, Daratumumab Biosimilar HLX15, Daratumumab-fihj

  • Given IV/PO

    Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex

  • Given PO

    Also known as: CC-5013, CC5013, CDC 501, Revlimid

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA scan

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureEchocardiography

    Undergo ECHO

    Also known as: EC

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: chest x-ray

06

What researchers measure

Primary outcomes

  1. Rate of Sustained Minimal Residual Disease (MRD) Negativity

    MRD negative status at any point, with a repeated MRD negative status one year later. All subjects meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable, with the exception of subjects determined to be a major violation. The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, \>\>\> 2016) was used for response assessment.

    Time frame: 1 year

Secondary outcomes

  1. Overall Response Rate

    The overall response rate will be defined as the percentage of patients that achieved confirmed very good partial response (VGPR) or better by The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, 2016) at the designated timepoint.

    Time frame: At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment)

  2. Overall Survival

    Defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.

    Time frame: 3 years

  3. Progression-Free Survival

    Defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.

    Time frame: 3 years

  4. Incidence of Adverse Events

    Adverse Events: All eligible subjects that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each subject, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the trial treatment will be taken into consideration. AEs will be summarized overall, as well as by treatment phase (induction, consolidation, maintenance with carfilzomib and lenalidomide and daratumumab). The percent of patients with a grade 3 or higher event will be reported for both the Induction and Consolidation timepoints.

    Time frame: Monthly up to 3 years after start of induction treatment

Other outcomes

  1. Clonal Architecture Before Treatment

    To determine the clonal architecture before treatment, after treatment in subjects with residual disease and in subjects who have disease progression after attaining MRD negativity.

    Time frame: Before and after treatment, up to two years or 24 months

  2. Bone Marrow Microenvironment

    To evaluate the bone marrow microenvironment before and after treatment and the time of MRD negative state.

    Time frame: Before and after treatment, up to two years or 24 months

07

Results

Posted Nov 2, 2026

Participant flow

Induction
Participant flow — Induction
MilestoneTreatment (Combination Chemotherapy)
Started17
Completed5
Not completed12
Withdrew: Adverse event1
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject1
Withdrew: Ineligible1
Withdrew: Alternative treatment1
Withdrew: Physician decision7
Consolidation
Participant flow — Consolidation
MilestoneTreatment (Combination Chemotherapy)
Started5
Completed0
Not completed5
Withdrew: Lack of efficacy2
Withdrew: Withdrawal by subject1
Withdrew: Premature study closure2
Maintenance
Participant flow — Maintenance
MilestoneTreatment (Combination Chemotherapy)
Started0
Completed0
Not completed0

Outcome measures

PrimaryRate of Sustained Minimal Residual Disease (MRD) Negativity

MRD negative status at any point, with a repeated MRD negative status one year later. All subjects meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable, with the exception of subjects determined to be a major violation. The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, \>\>\> 2016) was used for response assessment.

Time frame:
1 year
Reported as:
Number · percentage of patients
Rate of Sustained Minimal Residual Disease (MRD) Negativity
percentage of patientsTreatment (Combination Chemotherapy)
Rate of Sustained Minimal Residual Disease (MRD) Negativity11.8
SecondaryOverall Response Rate

The overall response rate will be defined as the percentage of patients that achieved confirmed very good partial response (VGPR) or better by The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, 2016) at the designated timepoint.

Time frame:
At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment)
Reported as:
Number · percentage of patients
Overall Response Rate
percentage of patientsTreatment (Combination Chemotherapy)
At end of induction76.5
At end of consolidation17.7
SecondaryOverall Survival

Defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.

Time frame:
3 years
Reported as:
Median · months
Overall Survival
monthsTreatment (Combination Chemotherapy)
Overall SurvivalNA (NA to NA)
SecondaryProgression-Free Survival

Defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.

Time frame:
3 years
Reported as:
Median · Months
Progression-Free Survival
MonthsTreatment (Combination Chemotherapy)
Progression-Free Survival22 (14.9 to NA)
SecondaryIncidence of Adverse Events

Adverse Events: All eligible subjects that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each subject, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the trial treatment will be taken into consideration. AEs will be summarized overall, as well as by treatment phase (induction, consolidation, maintenance with carfilzomib and lenalidomide and daratumumab). The percent of patients with a grade 3 or higher event will be reported for both the Induction and Consolidation timepoints.

Time frame:
Monthly up to 3 years after start of induction treatment
Reported as:
Number · percentage of patients
Incidence of Adverse Events
percentage of patientsTreatment (Combination Chemotherapy)
Induction88.2
Consolidation40
Other pre-specifiedClonal Architecture Before Treatment

To determine the clonal architecture before treatment, after treatment in subjects with residual disease and in subjects who have disease progression after attaining MRD negativity.

Time frame:
Before and after treatment, up to two years or 24 months

Results for this outcome have not been posted.

Other pre-specifiedBone Marrow Microenvironment

To evaluate the bone marrow microenvironment before and after treatment and the time of MRD negative state.

Time frame:
Before and after treatment, up to two years or 24 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were followed for 2 years. Mortality was followed for 3 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Treatment (Combination Chemotherapy)0/17 (0%)2/17 (11.8%)17/17 (100%)
Consolidation Treatment (Combination Chemotherapy)0/5 (0%)2/5 (40%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventInduction Treatment (Combination Chemotherapy)Consolidation Treatment (Combination Chemotherapy)
Ventricular tachycardiaCardiac disorders0/171/5
Prostate infectionInfections and infestations0/171/5
Heart failureCardiac disorders1/170/5
DyspneaRespiratory, thoracic and mediastinal disorders1/170/5
Thromboembolic eventVascular disorders1/170/5
Most frequent other events
Showing 10 of 99
Most frequent other events
EventInduction Treatment (Combination Chemotherapy)Consolidation Treatment (Combination Chemotherapy)
FatigueGeneral disorders7/175/5
Lymphocyte count decreasedInvestigations16/175/5
AnemiaBlood and lymphatic system disorders9/174/5
Alanine aminotransferase increasedInvestigations2/174/5
Alkaline phosphatase increasedInvestigations6/174/5
Neutrophil count decreasedInvestigations7/174/5
Platelet count decreasedInvestigations9/174/5
White blood cell decreasedInvestigations9/174/5
DiarrheaGastrointestinal disorders4/173/5
Back painMusculoskeletal and connective tissue disorders4/173/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment (Combination Chemotherapy)
Mean61.47 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Combination Chemotherapy)
Female7
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Combination Chemotherapy)
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Combination Chemotherapy)
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American0
White14
More than one race0
Unknown or Not Reported1
08

Study locations

3 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Feb 2026, 40 months.

Results were first posted in Nov 2026, 8 months after primary completion.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's 40 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 11, 2022
StartActual
Sep 22, 2022
Primary completionActual
Feb 12, 2026
CompletionEst.
Sep 4, 2028
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRate of sustained minimal residual diseaseSustained Minimal Residual Disease (MRD) negativityNegativityTime frame: At 1 year → 1 year
Nov 2, 2026
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: Up to 3 years → 3 years
  • EditedProgression-free survivalFree SurvivalTime frame: Up to 3 years → 3 years
  • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 30 days after administration of study therapy → Monthly up to 3 years after start of induction treatment
  • ChangedBefore Overall response rate [>= confirmed very good partial response (VGPR)]Now Overall Response RateTime frame: End of induction, end of consolidation, and every 3 cycles of maintenance, up to two years or 24. One cycle is 28 days. → At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment)
  • Editedother outcomeClonal architecture before treatmentArchitecture Before TreatmentTime frame: Before and after treatment, up to two years or 24 months
  • Editedother outcomeBone marrow microenvironmentMarrow MicroenvironmentTime frame: Before and after treatment, up to two years or 24 months
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRate of sustained minimal residual diseaseSustained Minimal Residual Disease (MRD) negativityNegativityTime frame: At 1 year → 1 year
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: Up to 3 years → 3 years
    • EditedProgression-free survivalFree SurvivalTime frame: Up to 3 years → 3 years
    • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 30 days after administration of study therapy → Monthly up to 3 years after start of induction treatment
    • ChangedBefore Overall response rate [>= confirmed very good partial response (VGPR)]Now Overall Response RateTime frame: End of induction, end of consolidation, and every 3 cycles of maintenance, up to two years or 24. One cycle is 28 days. → At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment)
    • Editedother outcomeClonal architecture before treatmentArchitecture Before TreatmentTime frame: Before and after treatment, up to two years or 24 months
    • Editedother outcomeBone marrow microenvironmentMarrow MicroenvironmentTime frame: Before and after treatment, up to two years or 24 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05497804
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Sep 22, 2022
Primary completion
Feb 12, 2026
Completion
Sep 4, 2028 (estimated)
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Study contacts

Shaji K. Kumar, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Daratumumab · Dexamethasone · Lenalidomide

Start the discussion